Drug Transporter (DT) Information

General Information of DT
DT ID DTD0100
Gene Name SLC16A1
Protein Name Monocarboxylate transporter 1
Gene ID
6566
UniProt ID
P53985
TCDB ID
2.A.1.13.1
3D Structure

Modelled DT Structure

Method: loop building

Template PDB: 6LYY_A

Identity: 100%

Minimized Score: -1124.011 kcal/mol

Detail: Structure Info

Synonyms HHF7; MCT; MCT 1; MCT1; MCT1D; SLC16A1; Solute carrier family 16 member 1; hMCT1
DT Family Major Facilitator Superfamily (MFS)
Monocarboxylate Transporter (MCT) Family
Tissue Specificity Detected in heart and in blood lymphocytes andmonocytes (at protein level). Widely expressed.
Function This proton-coupled transporter can mediates the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Depending on the tissue and on cicumstances, mediates the import or export of lactic acid and ketone bodies. Required for normal nutrient assimilation, increase of white adipose tissue and body weight gain when on a high-fat diet. Plays a role in cellular responses to a high-fat diet by modulating the cellular levels of lactate and pyruvate, small molecules that contribute to the regulation of central metabolic pathways and insulin secretion, with concomitant effects on plasma insulin levels and blood glucose homeostasis.
Disease(s) Cerebrovascular disorder [ICD-11: 8B2Z]
Endogenous Substrate(s) Monocarboxylates
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(α) Mutation-induced Structural Variation
Mutation-induced Structural Variation (MSV)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(γ) Outward/inward-facing Conformation
Outward/inward-facing Conformation (OIC)

(δ) Xenobiotics-regulated Structural Variability
Xenobiotics-regulated Structural Variability (XSV)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            6 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Atorvastatin
 Approved Drug Info Hyperlipidaemia 5C8Z [1]
Doxorubicin
 Approved Drug Info Leukemia 2A60-2B33 [2]
Gabapentin enacarbil
 Approved Drug Info Postherpetic neuralgia 1E91.5 [3]
Gamma-hydroxybutyric acid
 Approved Drug Info Cerebrovascular disorder 8B2Z [4]
Pyruvic acid
 Approved Drug Info Nutritional deficiency 5B7Z [5]
Salicylic acid
 Approved Drug Info Dermatitis EA80-EA8Z [1]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            2 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Biotin
 Phase 4 Drug Info Biotin ingestion 5B5G [6]
Butyrate
 Phase 2/3 Drug Info Schizophrenia 6A20 [3]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Glycolic acid
 Preclinical Drug Info Melasma ED60.1 [7]

Drug-DT Affinity Assessed by Cell Line

 Investigative Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Milchsaure Investigative Drug Info Xenopus laevis oocytes-MCT1 Km = 4 microM [8]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Pyroglutamic acid Investigative Drug Info Oocytes-MCT1 Km = 4 microM [9]
References
1 H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
2 Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):904-17.
3 Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J. 2008 Jun;10(2):311-21.
4 Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos. 2007 Feb;35(2):201-8.
5 AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J. 2010 Jan 15;425(3):523-30.
6 Biotin. Biofactors. 2009 Jan-Feb;35(1):36-46.
7 Cidofovir peptide conjugates as prodrugs. Journal of Organometallic Chemistry, 2005, 690(10):2673-2678.
8 Distribution of monocarboxylate transporters MCT1-MCT8 in rat tissues and human skeletal muscle. Appl Physiol Nutr Metab. 2006 Feb;31(1):31-9.
9 Interaction of atorvastatin with the human glial transporter SLC16A1. Eur J Pharmacol. 2016 Oct 5;788:248-254.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.